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Statement from the Authors
In preparing this document the Authors aimed to pool current information on canine and feline mast
cell disease. The information was gathered from international studies and a emphasis was placed on
material and opinion with a strong evidence base. We intend it to form the basis of our understanding
in this disease at the current time and we anticipate that it will be particularly useful for the general
practitioner. It should be emphasized that the authors are presenting this work from a European
perspective.
1 Abstract
Mast cell tumours (MCT) are commonly encountered in small animal practice. This review outlines the
biology of mast cell disease, the physiological consequences of MCT and offers a ‘best practice’ app-
roach to clinical management of dogs and cats with mast cell disease. Diagnostic tests, conventional
management and novel treatments are discussed, and evidence-based recommendations are given.
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Key Points
• Mast cell disease is a common disease of dogs and should always be considered in the list of
differential diagnoses for a skin mass.
• Mast cell tumours can give rise to paraneoplastic disease associated with histamine or heparin
release from degranulating tumours.
• Diagnosis can be made by fine needle aspirate (FNA).
• Grade of the tumour is an important prognostic marker.
• The primary treatment modality for mast cell tumours is surgery.
• Radiation treatment is usually reserved as an adjunct to surgery where complete excision cannot
be achieved.
• Chemotherapy is used to:
• Reduce tumour burden prior to definitive surgery
• In high grade tumours or where there is evidence of systemic spread
• Postoperatively where a tumour has been incompletely excised and a further surgery is not
possible or radiation therapy is not available.
• Tyrosine kinase inhibitors are a new class of drug that may be used in instances of nonresectable
or recurrent mast cell disease where conventional therapy is not appropriate or available.
2 Introduction
2.1 Background
In March 2009, after a series of meetings and
the approval of the first receptor tyrosine kinase
(RTK) inhibitor drugs for the management of MCT,
the authors initiated this clinical guide to ‘best
practice’ in the management of canine and feline
MCT. Statements in these guidelines are based
on published papers, consensus opinion and the
authors’ own expert opinions.
2.2 Evidence-based medicine (EBM)
Individual references used to support statements
were classified according the scheme below. Where
multiple references were available, those with the
highest evidence level were cited. Where peer-
reviewed sources were lacking, statements are the
opinion of the authors (EBM grade IV).
2.2.1 EBM grading system
The grading system proposed by Roudebush et al.1
is used:
Grade I: At least one properly designed, ran-
domized controlled clinical study performed
in the target species.
Grade II: Evidence from properly designed
randomized controlled studies in animals of
the target species with spontaneous disease in
a laboratory or research animal colony setting.
Grade III: Appropriately controlled stud-
ies without randomization; appropriately
designed case–control epidemiologic studies;
studies using models of disease or simula-
tions in the target species; dramatic results
from uncontrolled studies; case series.
Grade IV: Studies conducted in other
species; reports of expert committees, descrip-
tive studies; case reports; pathophysiologic
justification; opinions of respected experts.
3 Biology and function of mast cells
Mast cells arise as precursors in the bone marrow
and then migrate to the peripheral tissues where,
under the influence of local cytokines, they differen-
tiate into mature mast cells. In normal animals, mast
cells are present in most tissues, especially where the
body meets the environment (skin, mucosal sur-
faces). They are occasionally seen in the bone mar-
row, but almost never in the systemic circulation.2
Mast cells contain cytoplasmic granules harbour-
ing a large number of bioactive constituents, such as
histamine and heparin, involved in hypersensitivity,
allergy and inflammatory processes. These granules
stain metachromatically with toluidine blue.2,3
Mast cell tumours (MCT) are neoplastic
proliferations of mast cells. Cutaneous MCT
arise from tissue mast cells in the dermis and
subcutaneous tissues.
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e4 L. Blackwood et al.
4 CanineMCT
4.1 Incidence and signalment
MCT account for 16–21% of skin neoplasms in
dogs. Tumours are usually solitary, though a sig-
nificant proportion of dogs present with multiple
tumours. MCT usually occur in older dogs (mean
age 9 years), but may occur in dogs under 1 year of
age also. There is no gender predilection. Boxers,
Retrievers, Pugs, Boston terriers and Pit-Bull
terriers are at a higher risk of developing MCT.
However, in Boxers and Pugs, MCT are commonly
histologically low or intermediate grade, carrying a
more favourable prognosis. Shar-Peis, particularly
young individuals, are also predisposed to develop-
ing MCT, and these are often poorly differentiated
and biologically aggressive4–8 (EBM III). The
aetiology of MCT in the dogs is unknown.
4.2 Clinical presentation
4.2.1 Lesion
MCTs may develop anywhere on the body, and
are usually cutaneous (dermal) or subcutaneous.
Various forms exist:
Well-differentiated cutaneous MCT are slow
growing, hairless, solitary lesions and are
often present for months (Panel 1A).
Poorly differentiated MCT are rapidly grow-
ing, ulcerated and pruritic lesions some-
times with small ‘satellite lesions’ close by
(Panel 1B). There may be evidence of
local lymphadenopathy or organomegaly on
abdominal palpation.
A significant minority of subcutaneous MCT
look and feel like lipomas (Panel 1C).
Some 10–21% of dogs develop multiple
primary MCT either at initial presentation
or as subsequent events (EBM III).8–11 Care
should be taken to distinguish these dogs from
those suffering from regrowth or a poorly
differentiated tumour with satellite lesions.
4.2.2 Clinical behaviour
The gross appearance of MCTs correlates to some
extent with histological grade, and a tumour that
looks aggressive is almost certainly aggressive, but
a tumour that appears quiescent should not be
assumed to be benign. Clinical signs suggestive of
aggressive behaviour include (EBM III)6,8:
(1) Rapid growth
(2) Local irritation/inflammation
(3) Local infiltration/poor demarcation
from adjacent tissues
(4) Ulceration
(5) Satellite nodules
(6) Paraneoplastic signs.
MCT that remain localized and are present
for prolonged periods (months to years) without
significant changes are usually benign12 (EBM III).
Occasionally, manipulation during examination
may cause mast cell degranulation, producing
erythema and wheal formation, the so-called
‘Darier’s sign’.
MCT occur infrequently in mucosal sites.
Rarely, dogs present with disseminated or systemic
Panel 1. Examples of the clinical appearance of canine MCT. Well differentiated MCT (A), Poorly differentiated MCT (B)
and subcutaneous MCT (C).
© 2012 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 10, 3, e1–e29
European consensus document on mast cell tumours e5
Panel 2. The natural history of canine MCT. Growth of the tumour can cause local ulceration and swelling. Spread of the
tumour is normally to local lymph nodes and ultimately to liver and spleen.
mastocytosis, affecting lymph nodes, spleen, liver
and bone marrow. The natural history of canine
MCT is depicted in Panel 2.
4.2.3 Paraneoplastic disease
Dogs may present with so-called paraneoplastic
clinical signs, due to the release of bioactive con-
stituents, such as histamine, heparin and proteases
from mast cell granules (EBM III).4,6–8 Locally,
these substances cause oedema, ulceration and
swelling at the primary tumour site, and possi-
bly delayed wound healing and local coagulation
abnormalities (Panel 3).
The most common systemic effects are gastroin-
testinal (GI) signs. Histamine released by neoplastic
mast cells stimulates gastric H2 receptors, lead-
ing to hydrochloric acid oversecretion and gastric
hypermotility (EBM III).13 Clinical signs secondary
to ulceration include vomiting, GI haemorrhage,
anorexia and abdominal pain. Secondary iron defi-
ciency anaemia or peritonitis due to GI perforation
may occur. Necropsy studies report GI ulceration
in 35–83% of MCT patients (EBM III).14
Rarely, a sudden, massive release of histamine
from neoplastic cells may cause an acute anaphy-
lactic reaction, and episodes of collapse. Dogs with
extensive disease are particularly at risk.
4.3 Diagnostic approach
A cutaneous mass that increases and decreases
in size is suggestive of MCT. However, MCT can
look like any other skin lesion, and any skin lesion
Panel 3. Mast cells contain vasoactive granules.
Degranulation in mast cell tumours can cause localized
swelling, oedema and bleeding. In severe cases this can cause
systemic anaphylaxis.
will benefit from a fine needle aspirate (FNA) for
diagnosis.
4.3.1 Fine needle aspirate
FNA cytology gives a diagnosis for 92–96% of
MCTs15 (EBM II). Mast cells readily exfoliate
and are easily identifiable by metachromatically
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Panel 4. The cytological appearance of mast cell tumours. (A) Represents a typical MCT cytology demonstrating
metachromatically staining intracytoplasmic granules. Special stains will identify these granules (toluidine blue, pinacyanol,
Wright’s or Wright-Giemsa stain). Poorly differentiated mast cell tumours may lack these granules (B).
staining intracytoplasmic granules (Panel 4).
Special stains will identify these granules (toluidine
blue, pinacyanol, Wright’s or Wright-Giemsa
stain). Poorly differentiated MCT may lack these
granules. FNA will give a diagnosis but not a
tumour grade, though a cytologist will suspect a
high grade tumour if the cells are very pleomorphic.
For an accurate grade, histopathology is required.
FNA is inexpensive, can be performed with the
animal conscious and allows for better planning of
surgery (appropriate margins).
4.3.2 Incisional biopsy
Incisional biopsy involves taking a sample of the
mass without attempting to remove it completely.
This allows planning of the definitive surgical proce-
dure once the mass has been diagnosed and graded
by histopathology. When taking the incisional
biopsy, avoid areas of obvious inflammation or
necrosis and place the incision so the entire biopsy
tract can be resected at definitive surgery. Draw-
backs to incisional biopsies compared to FNA are
the risk of wound breakdown and the increased cost.
4.3.3 Excisional biopsy
Excisional biopsy is the removal of the mass for
histopathological evaluation. If you have an FNA
diagnosis of MCT and the tumour is in a site
where wide surgical excision can be performed,
then excisional biopsy is appropriate. In some
circumstances, such as difficult surgical sites, this
approach does not allow the surgery to be planned
properly. Since the first surgery is the best chance
of cure (as with fascial planes uninterrupted, and
no scar tissue, the macroscopic tumour is easily
envisaged) excisional biopsy in these sites could
jeopardise the chance of a surgical cure16 (EBM III).
For the best diagnostic approach, see the
algorithms in Figs 1 and 2.
4.4 Staging
Once the diagnosis of MCT has been made,
appropriate staging should be carried out. Staging
defines the nature and extent of disease. MCTs
metastasise to draining lymph node(s), liver, spleen
and bone marrow and can give rise to local
cutaneous satellite lesions.
Most dogs will have tumours that are unlikely
to metastasise, and not every patient requires full
staging. However, if an extensive or expensive treat-
ment is planned or a poorly differentiated tumour
has been identified, staging is recommended. Full
staging should include FNAs of draining lymph
nodes and abdominal ultrasound as a minimum.
Up to 24% of normal dogs will have a low number
of morphologically normal mast cells identified on
cytology in a lymph node17 (EBM III). Difficulties
in interpretation arise when small numbers of
© 2012 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 10, 3, e1–e29
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Figure 1. Diagnostic algorithm for a cutaneous mass (Note: cytology is not a substitute for histopathology. Histopathology
should be performed after excision of the mass).
Figure 2. Work-up algorithm following MCT diagnosis based on cytology of FNA.
apparently normal mast cells are seen in FNAs from
local or regional nodes, and the cytologist cannot
tell if they are reactive or neoplastic. However, as
a general rule, if mast cells appear in clusters or
sheets, this is suggestive of metastatic disease. Very
large numbers of mast cells, abnormal mast cells, or
an effacement of normal lymph node architecture
on histology, all point to metastatic disease. In
recent years the value of examining buffy coat
smears in dogs has been questioned18 (EBM I).
Most oncologists agree that buffy coat examination
in the dog has limited value in cases of mast cell
disease. However, this is still appropriate for cats
with certain presentations of mast cell disease.
For patients with nodal metastasis, full staging
is required including abdominal ultrasound and
eventually bone marrow aspiration and lung
radiographs. In these cases, abdominal ultrasound
should be accompanied by spleen and liver
aspiration whatever their sonographic features
(EBM III).19,20
4.5 Prognosis
The behaviour and progression of MCT is
highly variable. However, the histological grade
is the most important single prognostic factor
for MCT.
© 2012 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 10, 3, e1–e29
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Table 1. Histological criteria for grade of mast cell tumours (Patnaik et al.21)
Grade Histological criteria
1 Well differentiated Monomorphic round cells with distinct cytoplasm, medium-sized intracytoplasmic granules, no
mitotic figures noted.
Compact groups or rows of neoplastic cells confined to dermis.
2 Intermediately
differentiated
Some pleomorphic cells round to ovoid in shape. Some cells having less distinct cytoplasm with
large and hyperchromatic intracytoplasmic granules, but others have distinct cytoplasm with fine
granules. Areas of oedema or necrosis are noted. Mitotic figures are 0–2 per high power field.
Tumour infiltrating lower dermis/subcutaneous tissue.
3 Poorly differentiated Dense sheets of pleomorphic cells with indistinct cytoplasm with fine or not obvious
intracytoplasmic granules. Mitotic figures 3–6 per high power field. Oedema, haemorrhage,
necrosis and ulceration common.
Tumour infiltrating lower dermis/subcutaneous tissue.
4.5.1 Histopathology
The Patnaik system is most widely used for
cutaneous tumours21 (EBM III), and differentiates
MCTs into grade I (well differentiated), II
(intermediately differentiated) or III (poorly
differentiated) tumours (Table 1). Most grade I
MCTs are benign, develop slowly and persist for
years without increasing in size. Less than 10% of
grade I MCT metastasise, and grade I tumours in
general are unlikely to cause death of the patient.
Grade III tumours show aggressive growth and
have a high recurrence potential. More than 80%
of grade III tumours metastasise and frequently
cause death22 (EBM IV). The prognosis for grade
II tumours is variable. Many can be cured by
local surgery and only 5–22% of grade II tumours
metastasise. However, grade II tumours may cause
death in 17–56% of cases due to local treatment
failure or metastatic disease. Indicators of prognosis
for grade II MCTs would allow the selection of
patients with tumours requiring adjunctive therapy.
In addition to the unpredictable behaviour of
grade II tumours, histopathological grading is
subjective, resulting in grading variation between
pathologists. Several studies, including a recent
study in 95 dogs, showed that concordance among
pathologists was 75% for the diagnosis of grade
III MCT and less than 64% for the diagnosis
of grade I and II23,24 (EBM II). The World
Health Organization (WHO) clinical staging system
for canine MCT does not correlate clearly with
prognosis, so it is not used in a clinical setting4,11,25
(EBM III). To improve concordance between
pathologists, a two-tier histologic grading system
has recently been suggested24 (EBM II). In this
system, the diagnosis of high-grade MCTs is based
on the presence of any one of the following criteria:
(1) At least 7 mitotic figures in 10 high-power
fields (hpf)
(2) At least 3 multinucleated (3 or more
nuclei) cells in 10 hpf
(3) At least 3 bizarre nuclei in 10 hpf
(4) Karyomegaly (i.e. nuclear diameters of at
least 10% of neoplastic cells vary by at
least two-fold).
All other tumours are considered low grade.
According to the novel grading system, high-grade
MCTs were significantly associated with shorter
time to metastasis or new tumour development,
and with shorter survival time. The median survival
time was less than 4 months for high-grade MCTs,
but more than 2 years for low-grade MCTs.
Currently, the Patnaik system is still the most
widely used grading system for MCT in the dog.
However, the two-tier system described by Kiupel
may become more widely adopted by pathologists.
4.5.2 Lymph node pathology
Confirmed lymph node metastasis carries a poor
prognosis11 (EBM III), but interpretation of nodal
involvement is challenging26,27 (EBM III).
4.5.3 Anatomic location
MCTs that develop in mucocutaneous junctions
and in the inguinal region have historically been
reported to be more malignant regardless of
histological grade, but this is controversial28,29
© 2012 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 10, 3, e1–e29
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(EBM III). The poorer prognosis in these sites
may also be due to the difficulty of performing
adequate surgery in these locations.
Tumours involving the viscera, intestine or bone
marrow usually carry a poor prognosis30–33 (EBM
III/IV).
4.5.4 Clinical features
The clinical signs of aggressive behaviour (see
section Clinical behaviour) are usually associated
with poor prognosis.
4.5.5 Treatment failure
Recurrence of MCT after surgical removal has
been associated with a more guarded prognosis8
(EBM III).
4.5.6 c-Kit expression
The RTK c-Kit is dysregulated in 15–40% of
canine MCT, usually due to mutations in the c-Kit
gene. This dysregulation is associated with a poor
clinical outcome, increased risk of metastasis and
local recurrence and a higher tumour proliferation
index34,35 (EBM III/IV).
4.5.7 Proliferation markers
Markers of cell proliferation can predict prognosis
and response to therapy, and may be less subjective
than other prognostic indicators (see Table 2).
4.5.7.1 Mitotic index. The mitotic index (MI)
is the number of mitoses per 10 high power
fields, determined by standard histopathology
and should be provided in every histopathology
report.
In a study by Romansik et al.36 (EBM III) median
survival for dogs with a tumour having a MI of 5 or
less was 70 months, compared to 2 months where
the MI was greater than 5, irrespective of grade.
Early work also showed that patients with tumours
with a MI of 10 or more had a survival time of
only 11 weeks37 (EBM III). More recently, a cut-off
value for MI of 7 rather than 5 has been proposed38
(EBM III). The impact of MI on the likelihood of
recurrence was unclear, but Kiupel et al.24 (EBM II),
showed the importance of MI in predicting likely
recurrence in his the two-tier classification system
(described above).
4.5.7.2 Ki-67 protein. The Ki-67 protein is a
marker for proliferation, expressed during the cell
cycle. It can be detected by immunohistochemistry.
Ki-67 expression is significantly associated with
MCT prognosis, independent of tumour grade39,40
(EBM III). In the Scase study,40 Cox regression
models indicated that the Ki-67 score and mean
argyrophilic nucleolar organizing regions (AgNOR)
score were significantly associated with Patnaik
grade and survival time. A binary Ki-67 variable
(cut-off point Ki-67 score = 1.8) was a significant
predictor of survival for dogs with grade II
MCT. The estimated 1-, 2- and 3-year survival
Table 2. Cell proliferation markers with a prognostic value in cutaneous mast cell tumours in dogs
Parameter Significance Comment References
Mitotic index (MI) >5 prognostic for reduced survival
independent of grade.
>7 predictive for recurrence.
Useful test that can be carried out on
routine histological sections. Some
recommend 7 as cut off, rather than 5.
24, 36–38
Ki-67 High Ki-67 expression is associated with
increased mortality, recurrence and
metastasis. Prognostic factor
independent of histological grade.
Useful if available as proven
independent of grade.
39–41
Agyrophilic nucleolar
organiser regions
(AgNORs)
Higher AgNOR counts associated with
increased likelihood of death,
recurrence and metastasis.
Not a prognostic indicator independent
of histological grade, but may support
decision making for grade II tumours.
40, 42
Proliferating cell nuclear
antigen (PCNA)
Increased PCNA expression associated
with increased mortality. Not
consistently with increased risk of
recurrence or metastasis.
Not a prognostic indicator without
histological grade.
Not predictive of survival.
39, 40, 42
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probabilities for dogs with grade II MCT and
Ki-67 scores less than 1.8 were 0.92, 0.86 and
0.77, respectively. The corresponding survival
probabilities for dogs with grade II MCTs and Ki-
67 scores higher than 1.8 were 0.43, 0.21 and 0.21,
respectively. Higher Ki-67 index values indicate a
more proliferative tumour (>1.8) and, for dogs
with a solitary cutaneous MCT, may be a useful
prognostic parameter, particularly in dogs with
grade II tumours when used alongside the Patnaik
grading system41 (EBM III).
4.5.7.3 AgNOR proteins. AgNOR proteins are
argyrophilic nucleolar organizing region-associated
proteins that bind silver molecules, and can be
visualized using a silver-based histochemical stain.
The number of AgNOR dots per neoplastic nucleus
is inversely proportional to the doubling time.
AgNOR counts are associated with survival times,
but cannot predict clinical behaviour independent
of histological grade40,42 (EBM III). However,
higher AgNOR counts (with a cut-off value of 2.25)
were indicative of MCT with a higher probability
of metastasizing, with a lower AgNOR count
corresponding to a significantly longer survival
period. Cox regression models indicated that the
Ki-67 score (hazard ratio, 1.92; P< 0.001) and
mean AgNOR score (hazard ratio, 2.57; P< 0.001)
were significantly associated with Patnaik grade
and survival time. This study shows that both
mean AgNOR score and Ki-67 score are prognostic
markers for canine MCTs.
4.5.7.4 Proliferating cell nuclear antigen. The
proliferating cell nuclear antigen (PCNA) is a
protein required for DNA synthesis. Its expression
is associated with cell proliferation.
Box 1: When to refer anMCT patient to a specialist
(1) Challenging surgical site
(2) Case suitable for radiotherapy
(3) Case suitable for chemotherapy/TKI treatment.
PCNA expression is significantly higher in
recurrent versus nonrecurrent tumours and in
metastasic versus nonmetastatic tumours. How-
ever, it is not independent of histological
grade39,42 and is not predictive of survival time40
(EBM III).
4.6 Subcutaneous MCT in dogs
Until recently there was limited information about
prognostic assays used on MCT that arise in
the subcutis. Thompson et al.43 (EBM III) have
described the utility of KIT immunohistochemical
labelling pattern, c-Kit mutational status (presence
of internal tandem duplications in exon 11), and
proliferation markers – including MI, Ki67 and
AgNOR – as independent prognostic markers for
local recurrence and/or metastasis in canine subcu-
taneous MCT. Sixty subcutaneous MCT in 24 dogs
with local recurrence and 12 dogs with metastasis
were compared to dogs matched by breed, age
and sex with subcutaneous MCT that did not
experience these events. MI, Ki67, the combination
of Ki67 and AgNOR and KIT cellular localization
pattern were significantly associated with local
recurrence and metastasis, thereby demonstrating
their prognostic value as a panel for subcutaneous
MCT. No internal tandem duplication mutations
were detected in exon 11 of c-Kit in any tumours
in this study, but numbers were low.
4.7 Treatment
The treatment options for MCT depend on the
clinical features, clinical stage and grade. The main
questions should be:
(1) Is surgical excision possible?
(2) Is local therapy sufficient or is systemic
therapy also required?
A treatment algorithm is shown in Fig 3A and
B. In addition, a guide for practitioners to identify
when to refer cases to a specialist is given in Box 1.
4.7.1 Surgery
Surgery is the treatment of choice in local-
ized, nonmetastatic canine MCTs (EBM
III/IV).44,45
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A
B
Figure 3. (A) Treatment algorithm for a cutaneous mass without signs of metastasis. If more than one treatment option is
given, they are listed in order of preference. (B) Treatment algorithm for a cutaneous mass if no grade is available and FNA
suggests involvement of the regional lymph node. If more than one treatment option is given, they are listed in order of
preference.
MCT may degranulate in response to surgical
manipulation. Particularly where there is bulky
disease, perioperative administration of H1- and
H2-blockers is recommended to reduce the risk of
local and systemic effects8 (EBM IV).
4.7.1.1 Surgical margins. Historically (since the
1960s), a 3-cm margin in all directions has been
recommended for excision of MCTs, while the
deep margin should include at least one fascial
plane (EBM IV)4,8,44 (Panel 5).
© 2012 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 10, 3, e1–e29
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A B
C D
Panel 5. Simple excision of a grade II MCT (A) demonstrating wide (2–3 cm) surgical margins (B, C) and reconstruction
of the wound (D).
More recent studies show that for most grade I
and II MCTs, a lateral margin of 2 cm and a deep
margin of one fascial plane is sufficient10,46,47 (all
EBM III). In a more recent retrospective study,
excision of both grade I and II MCTs (of between
2 and 31 mm) with a lateral margin of at least
1 cm and a deep margin of at least 4 mm did
not result in recurrence48 (EBM III). Therefore,
it is reasonable to conclude that a less aggressive
resection does not result in a higher recurrence
rate for smaller low-grade tumours, and facilitates
wound reconstruction. The deep margin should
include the panniculus muscle (if present), the
underlying fascia or, in its absence, the superficial
layer of the musculature46,47,49 (all EBM III). Where
there are concerns regarding margins, biopsies
should also be submitted from the tumour bed.
This ‘2cm/one fascial plane’ recommendation
has not been evaluated for large tumours greater
than 4 cm in diameter. In addition, higher-grade
tumours are more locally invasive and the rule
cannot be recommended for these tumours.
Grade III tumours should be excised with a
lateral margin of at least 3 cm plus the deep fascial
plane. However, as the risk of local recurrence
and metastasis is high, multimodal treatment is
preferred8 (EBM IV).
4.7.1.2 Tumours in difficult locations. Tumour
location may influence the feasibility of wide local
excision. Most often, it is the deep margin that
is challenging, in areas such as the distal limbs or
face. Even obtaining adequate lateral margins may
be challenging in areas of limited skin, particularly
the limbs distal to mid antebrachium or hock, and
reconstructive surgery is often required (e.g. free
grafts, axial pattern flaps). It should also be noted,
however, that Brocks et al.38 (EBM I) reported that
a 0.5 cm or less excisional surgical margin for MCT
on distal limbs gave a 2-year recurrence-free rate
of 93%. The goal of this study was to evaluate the
ability of hypotonic water to reduce the recurrence
rate in incompletely resected MCT, in particular
those in difficult locations where 0.5 cm margins
could not be achieved. Treatment with hypotonic
water did not prevent recurrence, and prognosis
was determined by the histological grade. However,
based on the results of this study, a 0.5 cm resection
cannot be recommended as local infiltration with
hypotonic water is a confounding variable. It is the
authors’ opinion that further studies are necessary
before a surgical excision less than 1 cm may be
recommended, even for apparently low grade
canine MCT.
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Neoadjunctive chemotherapy or prednisolone
therapy can be used to make the tumour more
amenable to surgery50 (EBM III). Where com-
plete excision remains impossible, a conservative
(cytoreductive or marginal) resection followed by
adjuvant radiotherapy is usually preferred over a
radical surgical procedure22 (EBM IV) and (EBM
III).51–54 Small molecule tyrosine kinase inhibitors
(TKIs) have also shown efficacy in nonresectable
MCT (toceranib and masitinib)a.
The use of adjuvant radiotherapy following
reconstructive surgery may lead to complications
(EBM III55). Chemotherapy has also been suggested
as an alternative to radiation for incompletely
excised canine cutaneous grade II MCTs56,57
(EBM III).
4.7.1.3 Histological examination of surgical
margins. The histological evaluation of margins
can be defined as:
(1) Complete resection (no tumour cells
within 1 mm of the surgical margin)
(2) Complete but close (mast cells within
1 mm of the surgical margin), or
(3) Incomplete (mast cells at the surgical
margin)50 (EBM III).
The presence of sheets or clusters of mast cells
with features of malignancy at the resection margins
should be interpreted as incomplete excision. How-
ever, if there are sparse mast cells on the periphery
of the excised tissue, it can be difficult to tell if
these are tumour cells or just physiologic mast cells
attracted by chemotaxis33,41,47,49,58 (all EBM III).
Many apparently incompletely excised solitary
grade II MCT do not recur10,45–47,49,55,59 (all EBM
III), suggesting that some of the observed mast
cells on the periphery may not be neoplastic. In
addition, even after apparently complete surgical
resection local recurrence may occur in 5–23%
of the cases10,15,55,59 (all EBM III). However, the
recurrence rate in cases with nonclean margins
is significantly increased compared to clean
resections60 (EBM III).
Treatment recommendations depend on the
margins found at histopathology (see Fig 3A and B):
aPalladia® – Summary of product characteristics EMA 2009.
(1) For grade I and II tumours with
histologically complete excision and
‘clean’ tumour bed biopsies, no adjuvant
therapy is required, but monitoring is
recommended. In case of pre-existing
metastatic disease, adjunctive treatment
is required.
(2) For grade I and most grade II tumours,
where incomplete margins are reported
but without gross disease and where
the wound has healed uneventfully,
the preferred option is to perform an
‘en bloc’ excision of the scar with
2 cm margins. Alternatively follow-up
radiotherapy can be performed, or
the site can be monitored. However,
if margins are incomplete/narrow and
there is macroscopic residual disease,
recurrence, or metastasis, a ‘wait and
see’ approach is never appropriate. The
situation with microscopic disease alone
is a difficult decision as only one-third
of grade II tumours in this category are
reported not to grow back55 (EBM III).
(3) Surgery in dogs with nodal metastases.
In grade I and II MCTs with likely or
confirmed local lymph node involve-
ment, the treatment of choice is com-
bined surgery and radiotherapy. Good
outcomes with a median disease-free
interval of 40.6 months have been found
for combined therapy with surgery and
irradiation54 (EBM III) and (EBM IV).22
Chemotherapy should also be considered
in these patients56 (EBM III).
4.7.1.4 Surgery in dogs with multiple MCT. In
multiple MCTs, all tumours amenable to surgery
should be excised. The prognosis for multiple
MCTs is not generally worse than that for solitary
tumours6,11 (EBM III).
4.7.2 Radiotherapy
Complete surgical excision should be considered
the best local treatment for MCT, and radiation
therapy should be restricted to cases where surgery
cannot achieve local control. If a second surgery
with wider margins around the surgical scar can be
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carried out, this may provide a complete excision,
and this option should be considered. However,
radiotherapy can also be used to treat local/regional
nodal metastases.
Radiotherapy is generally avoided as a sole
therapy where there is bulky disease due to the
risk of radiation-induced mast cell granulation and
serious systemic effects. Larger tumour volume is
also associated with shorter disease-free interval53
(EBM III). Larger tumours are more likely to
contain radiation-resistant tumour cell clones and
areas of radio-resistant tissue due to micro-
environmental factors such as hypoxia, and are
also more difficult to irradiate.
Radiotherapy is most often used as a postoper-
ative adjunctive therapy after incomplete excision.
Best results are achieved where radiation is planned
or considered prior to surgery, rather than as
an afterthought after an inadequate surgery. In
order to maximize the chances of a good outcome,
accurate recording of the presurgical tumour is
required (photographs or sketches, dimensions),
to ensure there is not a ‘geographical miss’. A ‘miss’
occurs when tissue that was originally within the
planned treatment margins of the tumour is not
included in the radiotherapy treatment field, mak-
ing recurrence more likely. Ideally, metal surgical
clips should be placed at the surgical margins: these
can be visualized by radiographs taken using the
radiotherapy machine during treatment (portal
imaging). Clips are especially useful on the trunk,
body wall and proximal limbs where there may be
substantial post surgical tissue migration.
The use of advancement flaps and grafting tech-
niques may increase the field size for treatment
and result in a delay in starting radiation therapy
because of delayed wound healing or wound break-
down. A conservative surgery with primary closure
may be preferable when postoperative radiation
therapy is planned. In particular, consideration
should be given to simpler techniques when a flap
or graft procedure will only allow an increase in
lateral margins, but does not alter deep margins.
On the limbs, a strip of skin must be excluded
from the radiation field to prevent the development
of lymphoedema due to damage to the lymphatic
drainage. This means the whole circumference of
the limb cannot be irradiated, limiting margins.
Oblique and transverse incisions should be avoided.
Most centres offering radiotherapy will be able to
irradiate tumours of the limbs and extremities. For
tumours of the thoracic or abdominal wall, electron
or orthovoltage radiation may be required.
The prognosis for canine MCTs treated with
surgery and radiation is generally good, but
published data are difficult to interpret in view
of the relatively low rate of recurrence reported
with surgery alone, even in case of incomplete
histological margins49 (EBM III).
Adjuvant radiation therapy for intermediate
grade MCTs results in 1- to 2-year disease-free
intervals in 81–95% of cases51,52,54 (all EBM
III). Disease-free intervals of 40 months have also
been reported for dogs with grade I/II tumours
with regional lymph node metastases treated with
surgery and radiation60 (EBM III). Several different
fractionation regimes are reported and the ideal
protocol is unknown. However, where definitive
protocols are used, higher recurrence rates are
reported at less than 40 Gy total dose53 (EBM III).
There have been no randomized trials comparing
hypofractionated and definitive protocols.
Prednisolone therapy is often given to patients
before, during and for several weeks after radiother-
apy to reduce the severity of radiation-induced mast
cell degranulation and consequent adverse effects.
Similarly, H1-blockers such as chlorpheniramine
and H2-blockers such as cimetidine or ranitidine
are also administered to minimize the systemic
effects of mast cell degranulation.
4.7.3 Chemotherapy
Chemotherapy can be used in dogs in three ways:
(1) Where systemic rather than loco-regional
therapy is required, to treat, delay
or prevent disseminated metastases, in
high-grade tumours.
(2) In a neo-adjunctive setting, prior to
surgery or radiotherapy, to reduce
tumour burden (down-stage disease)
and improve the likelihood of achieving
complete excision, or to make it easier
and safer to irradiate the mass. However,
there are no studies properly evaluating
efficacy of chemotherapy in this setting.
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Prednisolone alone is also used in this
way50,61 (EBM III).
(3) To treat residual microscopic disease
where further surgery is not possible
and radiation therapy is not available.
Outcomes in this setting have only
been reported in 20 cases, where 18
dogs did not have local recurrence after
1 year62 (EBM III). These data should
be interpreted with care as many grade
II tumours were included, which have
a relatively low recurrence rate with
incomplete margins.
Systemic treatment with chemotherapy is most
appropriate for tumours with a high risk of
metastases: grade III tumours, tumours where the
pathologist suggests grade II/III features and grade
II tumours with risk factors for reduced survival
and/or metastases such as high proliferation
marker values.
Chemotherapy is most often used to delay
or prevent metastatic disease (in addition to
surgical treatment of the primary site), or to
delay progression of existing metastatic disease, but
efficacy studies are lacking. In one study, 61 dogs
with either grade III or II tumours thought to be at
high risk of metastasis were treated with prednisone
and vinblastine (following excision with or without
radiation therapy). All patients were alive 3 years
later, with a disease-free interval of 1305 days56
(EBM III). This compares favourably with historical
data on survival for patients with grade III tumours,
treated with surgery alone, where only 6–27% of
patients were alive after 1 year12,21,37 (all EBM III).
4.7.3.1 Drugs and protocols. The most common
chemotherapy protocols used to treat canine MCT
are summarized in Table 3. First-line therapy
often consists of vinblastine and prednisolone, and
second-line therapy of lomustine, but protocols
alternating vinblastine and lomustine are also
commonly used.
There is limited data to support the use of other
chemotherapeutic agents in the treatment of canine
MCTs. Good response rates have been reported with
combined vinblastine, cyclophosphamide (CYC)
and prednisolone, but the duration of response was
not better than other protocols, and the additional
potential toxicity without proven survival
advantage means this protocol has not become
established69 (EBM III). Chlorambucil and pred-
nisolone resulted in a measurable response in 8 of 21
(38%) cases, with a median progression-free inter-
val for responders of 533 days and a median survival
time of 533 days70 (EBM III). Single agent hydrox-
yurea resulted in a measurable response in 13 of 46
(28%) dogs for a median of 60 days71 (EBM III).
There are no randomized trials comparing the
survival advantage of different protocols in patients
with MCT with high risk of metastases.
Prednisolone is active against canine MCT, but
when used alone it has a low response rate, with only
20% of patients with measurable disease achieving
a complete or partial response (5 of 25 patients
responded, with survival times for those that died
due to progressive disease of 3, 5 and 6 months
for those with PR, and 22 months for one dog that
achieved CR72 (EBM III)).
4.7.3.2 Toxicity. The choice of a chemotherapeu-
tic drug should take account of its potential toxic
effect.
Vinblastine is a severe perivascular irritant and
must be given via a cleanly placed, first-stick intra-
venous catheter. It is also potentially myelosuppres-
sive and haematology must be checked prior to each
dose. The recommendation is that, in a general prac-
tice situation, drug should not be given if the neu-
trophil count is less than 3 × 109 L−1 or the platelet
count is subnormal. In some circumstances, oncol-
ogists may elect to treat patients with lower counts.
Myelosuppression is mainly seen in patients receiv-
ing weekly treatments (at the start of chemotherapy)
and the interval may need to be extended in some
patients. GI toxicity is generally mild.
Lomustine can be very severely myelosup-
pressive. Myelosuppression may be delayed,
and recovery slower than with other drugs.
Idiosyncratic severe thrombocytopenia can occur.
Haematology must be checked prior to each dose,
and the drug should not be given if there are
cytopaenias as above. Lomustine is also hepato-
toxic, and it is unclear if this is idiosyncratic or
related to total dose received. Monitoring of ALT is
recommended. There are no established guidelines,
but some oncologists suggest treatment should
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Table 3. Commonly used chemotherapy protocols for canine mast cell tumours (after Blackwood, BSAVA Manual of
Oncology, 3rd edition63)
Drug
Published total
response rate (sum of
complete and partial
responses for
measurable disease) Protocol Comment/toxicity
References
(EBM grade)
Vinblastine and
prednisolone
47.00% Vinblastine 2 mg m−2 IV
weekly for 4 weeks then
fortnightly for four further
treatments.
Prednisolone 2 mg kg−1 PO
once daily for 1 week, then
1 mg kg−1 daily for 2 weeks,
then 1 mg kg−1 every other
day.
6–20% toxicity:
myelosuppression and GI
toxicity.
Can roll vinblastine out to
6 months.
Dose escalation of vinblastine
may be possible in some
cases.
(EBM III)56,64,65
Lomustine 44.00% 70 mg m−2 PO q21d for
four cycles.
Lomustine is associated with
myelosuppression, GI and
hepatotoxicity.
Toxicity of longer term
monotherapy unknown if
lomustine continued.
Lomustine often used as rescue
therapy after vinblastine and
prednisolone.
(EBM III)66
Vinblastine/lomustine
(alternating
vinblastine/
lomustine, one
treatment q14d)
57% Vinblastine 2 mg m−2 IV
week 1 then every fourth
week.
Lomustine 60 mg m−2 PO
week 3 then every fourth
week.
Planned protocol 4–6 cycles
Toxicity in 54% of cases, mainly
myelosuppression.
(EBM III)67
Vinblastine/lomustine
and prednisolone
(alternating
vinblastine/
lomustine, one
treatment q14d)
Not published
(reported in
opinionated
review)
Vinblastine 2 mg m−2 IV
week 1 then every fourth
week.
Lomustine 70 mg m−2 PO
week 3 then every fourth
week.
Prednisolone 0.5 mg kg−1 PO
daily.
Protocol continues for 6 months. (EBM IV)22
Vinblastine/lomustine
and prednisolone
(alternating
vinblastine/
lomustine, one
treatment q14d)
65% Lomustine 70 mg m−2 PO
week 1 then every fourth
week.
Vinblastine 3.5 mg m−2 IV
week 3 then every fourth
week.
Prednisolone 2 mg lk−1 PO
daily for first 2 weeks then
1 mg kg−1 daily until week
24 then tapered over 4
weeks.
Of 48 dogs, 13 required
lomustine dose reduction and
17 required vinblastine dose
reduction, due to significant
myelosuppression. 33%
developed severe
neutropenia, 28%
hepatotoxicity.
CARE advised in general practice.
24-week protocol.
(EBM III)68
be stopped if ALT exceeds 250 IU L−1, or after a
maximum of six doses or 6 months treatment57
(EBM IV). One study reported fatality in 2 of 12
dogs with MCT, due to hepatotoxicity57 (EBM III).
However, co-administration of denamarin with
lomustine reduces drug-induced increases in liver
enzymes, and is thought to be hepatoprotective73
(EBM II/III).
4.7.4 Tyrosine kinase inhibitors
RTKs are an important group of cell surface
receptors that trigger cellular activation resulting
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in cell proliferation, differentiation and survival
when stimulated by their cognate ligands (see Box 2
with Figs 4 and 5). Normal kinase function is critical
to cell growth and differentiation, and dysfunction
of several RTKs has been characterized in a variety
of cancers. RTKs have also been implicated in new
blood vessel formation in tumours (angiogenesis)
and the process of metastasis.
Box 2: Receptor tyrosine kinases – Their role and inhibition
Tumours cannot grow more than a few millimetres without a blood supply. So-called endothelial
precursors are induced to grow into new blood vessels (angiogenesis), through stimulation of receptors
on their cell surface. These receptors, called receptor tyrosine kinase or RTKs, bind growth factors. RTKs
are activated following binding of the ligand to the extracellular domain of two receptor monomers.
This brings them together, and produces a receptor dimer, which activates protein kinase activity.
As a result of this activation, downstream signalling pathways within the cell are activated (Fig 4).
Transmission of signals to the nucleus leads to altered expression of a wide range of genes involved in
cell proliferation, survival and differentiation, allowing tumour growth and angiogenesis.
The activation steps depend on phosphorylation, which require ATP binding. This ATP binding is
often the target for inhibitory drugs (Fig 4).
Figure 4. The structure of a receptor tyrosine kinase.
Figure 5. Activity of RTK inhibition.
RTKs are dysregulated in certain cancers. Dysregulation may be due to overexpression, mutation,
chromosomal translocation or autocrine signalling. In these cases, growth factor is no longer needed.
One such RTK is called KIT, encoded by the c-Kit gene. Recent studies have found that mutations in c-Kit
may be associated with MCT development in dogs, particularly higher grade tumours: mutations are
found in about 30% of canine grade II and III MCT.34,74 These are gain-of-function mutations, causing
constitutive activation of the KIT receptor without the requirement for ligand binding. Inhibition of the
RTK will block ATP binding and the cascade of biochemical reactions (downstream signalling), leading
to a reduced proliferation, migration, apoptosis and angiogenesis, depending on the RTK targeted (Fig 5).
The normal activity of RTKs – such as the
platelet-derived growth factor receptor (PDGFR)
or the vascular endothelial growth factor receptor
(VEGFR) – may be utilized by the tumour stroma
to maintain angiogenesis, promote metastasis and
support the tumour niche environment.
Specific small-molecule TKIs are able to block
the activity of receptors by competitive inhibition
of ATP binding (Fig 5). Recently, two RTKIs
were approved by the European Medicines Agency
(EMA) for use in MCT in dogs:
Both were developed to target KIT75,76 (EBM III).
Toceranib also targets VEGFR2 and PDGFR, RTKs
that play an important role in tumour angiogenesis
and metastasis4 (EBM IV).
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Figure 6. Algorithm for TKI use in canine mast cell tumours. If consideration is being given to RTKI therapy, then it is
strongly recommended that you discuss the case with a specialist oncologist and follow close monitoring for potential
adverse reactions.
(1) Toceranib phosphate (Palladia®, Pfizer
Animal Health), approved for use in
recurrent, nonresectable grade II/III
MCTa.
(2) Masitinib (Masivet®, AB Science),
approved for use in nonresectable grade
II/III MCT with established c-Kit muta-
tion, which should be confirmed before
treatmentb.
Both drugs have demonstrated efficacy as single
agents in prospective clinical trials in dogs (EBM
I)77,78 and (EBM II/III).79
The efficacy of toceranib was demonstrated in
dogs with advanced recurrent cutaneous grade II/III
MCT with or without lymph node involvement77
(EBM I). Treatment with toceranib provided
a statistically significant improvement in the
objective response rate (ORR) versus placebo
in the blinded phase. The ORR for all dogs
receiving toceranib was 42.8% and the biological
response rate including dogs with stable disease
for more than 10 weeks was 59% (EBM I)c. The
presence of a c-Kit mutation and the absence
of regional lymph node metastasis, but not the
tumour grade, were significantly associated with
aPalladia® – Summary of product characteristics EMA 2009.
bMasivet® – Summary of product characteristics EMA 2008.
cPalladia® – Scientific discussion EMA 2009.
a higher objective response. Dogs with grade
II tumours and dogs without regional lymph
node metastasis had a longer time to tumour
progression (TTP). There was no significant
association between c-Kit mutation status and time
to tumour progression or duration of response77
(EBM I).
The efficacy of masitinib was studied in dogs
with nonresectable or recurrent grade II or
III MCT without nodal or visceral metastasis,
previously treated or not78 (EBM I). Treatment
with masitinib significantly prolonged time to
tumour progression in all dogs compared with
placebo, but this was not significant in dogs with
a mutant form of KIT receiving masitinib as
second-line or later treatment. Masitinib increased
overall survival only in MCT dogs expressing a
mutant form of KIT (c-Kit positive) and there
was no statistically significant difference between
masitinib and placebo at the 6-month evaluation78
(EBM I).
An additional study showed that masitinib used
as a first-line treatment increased 12 and 34 months
survival rate in dogs with nonresectable MCT79
(EBM II/III). However, current guidelines indicate
that RTKIs should not be considered as first-line
therapy. Although investigator-led studies are still
in progress, an algorithm for current recommended
usage is shown in Fig 6.
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RTKIs are a new and exciting class of drugs that
give the practitioner a further treatment modality
in treating MCT. However, all the potential
indications for this class of drugs are not yet known
in canine and feline with MCT and other type of
cancers and metastasis, especially when inhibition
of angiogenesis is involved.
The oral formulation makes this class of drugs
easier to administer. However, patients receiving
RTKIs should be closely monitored, as they
would be for conventional cytotoxic therapy (see
Box 3), as adverse drug-specific reactions have been
described with both licensed medications. The most
commonly reported clinical side effects reported
with the use of toceranib included diarrhoea,
anorexia, lethargy, vomiting, lameness and weight
loss77 (EBM I) and Palladia®a. The most common
side effects reported with masitinib were diarrhoea,
vomiting, oedema and neutropenia, but renal
disorders with protein losing nephropathy and
haemolytic anaemia have also been described78
(EBM I) and Masivet®b.
Box 3: Practicalities of RTKI usage in MCT
RTKIs are currently licensed in Europe for the treatment of recurrent MCT where surgical excision
is not possible or appropriate. If consideration is being given to RTKI therapy, then it is strongly
recommended that you discuss the case with a specialist oncologist and follow close monitoring for
potential side effects.
As a guide:
(1) These drugs are anti-cancer agents that, like conventional cytotoxic drugs, can cause side effects.
(2) Side effects reported in the literature are largely grade I/II (mild to moderate) but grade III/IV
(severe) can occur in some sensitive patients or where treatment is inappropriate. Side effects are
varied but include GI signs (diarrhoea) and effects of the haematopoietic system (neutropaenia).
Not every side effect is similar to those seen with conventional cytotoxic drugs. For example
muscle cramping is reported with toceranib and protein losing nephropathy with masitinib.
Close clinical monitoring is required (especially in the early stages of treatment)
(3) Complications of therapy can arise and may require treatment holidays or dose reductions. If
you are considering using this drug, based on the algorithm in Fig 6, then it is recommended
that you discuss the case with a specialist oncologist in referral practice first.
(4) RTKIs should not be considered as an alternative to surgical resection where this can be
performed in practice or by a specialist surgeon.
The beneficial and adverse effects of RTKIs and
chemotherapy drugs in combination are currently
being investigated.
aPalladia® – Summary of product characteristics EMA 2009.
bMasivet® - Summary of product characteristics EMA 2008.
4.7.4.1 RTKIs combined with conventional
chemotherapy drugs. Studies combining RTKs
with conventional chemotherapy drugs are cur-
rently lacking. However, recently a phase 1 clinical
study was conducted to evaluate the safety of com-
binations vinblastine and toceranib in dogs80 (EBM
III/IV). In this study, the dose-limiting toxicity for
the simultaneous combination was neutropenia
and the maximally tolerated doses were:
(1) Vinblastine (1.6 mg/m2 every other
week) concurrent with
(2) Toceranib (3.25 mg/kg PO, every other
day).
This represents greater than a 50% reduction in
dose-intensity for vinblastine (compared to single-
agent use) and as such does not support this
combination based on current drug combination
paradigms80 (EBM III/IV). While a strict adherence
to dose paradigms speaks against the combina-
tion, evidence of significant activity (71% objective
response) and enhanced myelosuppression sug-
gest additive or synergistic activity. A prospective
randomized evaluation comparing this combina-
tion with standard single-agent treatments needs to
be conducted to interrogate this possibility.
Interestingly, another recent prospective clinical
trial in client-owned dogs toceranib phosphate
and metronomic dosing of cyclophosphamide were
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combined in an attempt to improve tumour
control by suppression of regulatory T cells
(Treg) and restoration of T cell-mediated immune
responses81 (EBM II/III). Results demonstrated that
toceranib significantly decreased the number and
percentage of Treg cells in the peripheral blood
of dogs with cancer. Dogs receiving toceranib
and cyclophosphamide demonstrated a significant
increase in serum concentrations of IFN-γ , which
was inversely correlated with Treg numbers after
6 weeks of combination treatment. These data
support an immunomodulatory function of RTKIs
in cancer.
4.7.4.2 RTKIs combined with radiation
treatment. Recently, a multicentre prospec-
tive trial was conducted to establish the tolerability
of using toceranib phosphate in combination with
hypofractionated radiotherapy in nonresectable
MCT82 (EBM III). In this study, toceranib was
administered for 1 week before initiating RT,
consisting of a total of 24 Gy delivered in three
or four fractions. The overall response rate was
76.4%, with 58.8% of dogs achieving a complete
response and 17.6% a partial response. The median
time to best response was 32 days, and the median
progression-free interval was 316 days. The overall
median survival time was not reached with a
median follow-up of 374 days. These response rates
and durations were higher than those reported for
toceranib as a single-agent treatment for MCT, but
this study included the addition of prednisolone.
Predictably, the most common toxicities were
related to the GI tract and the liver.
On the basis of the current evidence, the
algorithm in Figure 6 can be used to determine
the role of RTKs in the management of MCT. As
new evidence emerges, this algorithm may change.
4.7.5 Other treatments
Less established treatments for canine MCTs
include local injection of corticosteroids or
deionized water, immunotherapy, cryotherapy,
hyperthermia and electrochemotherapy.
4.7.5.1 Intralesional corticosteroids. Intralesional
corticosteroids have been used in nonresectable
tumours and those that have failed other
treatments83–85 (all EBM IV). No controlled studies
have been performed to compare this with systemic
treatment.
4.7.6 Immunotherapy
Immunotherapy has been used in individual
cases86,87 (EBM IV). Initial response rates simi-
lar to single agent vinblastine have been described
using a preparation containing human chori-
onic gonadotropin and bacillus Calmette-Guerin88
(EBM III), but a large proportion of dogs were with-
drawn prior to completion of the 6-week protocol
so follow-up data was limited.
4.7.6.1 Intraregional deionized water. Intrare-
gional deionized water has been recommended as
an adjuvant after incomplete resection89–93 (all
EBM III), but not all trials demonstrate efficacy.
A recent randomized study has shown that hypo-
tonic water does not decrease local recurrence or
improve survival times in dogs with incompletely
excised solitary MCT38 (EBM I).
4.7.6.2 Hyperthermia. Hyperthermia – heating
tumour tissue to 40–45 ◦C – was used in
combination with radiotherapy in the 1980s94,95
(EBM IV). Additional benefit compared to
radiotherapy alone is unproven.
4.7.6.3 Photodynamic therapy. Photodynamic
therapy relies on local application of light of
certain wavelengths to activate systemically
delivered drugs, and has been used in MCT
(EBM IV)96–100,102, (EBM III/IV).101,102 Responses
are reported, but treatment may precipitate
degranulation, and is only suitable for relatively
small superficial lesions, which are likely to be
amenable to surgery.
4.7.6.4 Cryosurgery. Cryosurgery or cryotherapy
has been used to treat small (<1 cm) MCT16,103,104
(all EBM IV), but may cause mast cell degranula-
tion. The utility of this approach is limited to areas
with small tumours where a complete excision is
difficult103 (EBM IV).
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4.7.6.5 Electrochemotherapy. Electrochemother-
apy combines the administration of chemother-
apeutic drugs (cisplatin or bleomycin) with
application of electric pulses to the tumour
to increase local uptake of drug (EBM IV)105,
(EBM III).106,107 Complete and partial responses
have been reported in MCT (EBM III).106,107
Local cisplatin and electrochemotherapy has
been recently suggested as an alternative to
adjuvant radiotherapy for incompletely resected
MCT108 (EBM III). However, there are health and
safety considerations and this is therfore is not
recommended routinely (EBM IV).
4.7.7 Supportive therapy
Supportive care includes medication to counter the
effects of histamine release:
(1) H2 antagonists to treat gastric ulcer-
ation: cimetidine (4 mg/kg PO q8h),
ranitidine (2 mg/kg PO q12h), famoti-
dine (0.5–1 mg kg−1 PO q12–24h) or
the proton pump inhibitor omeprazole
(0.5–1 mg kg−1 PO q24h).
(2) H1 antagonists to decrease the adverse
effects of histamine release on peripheral
vasculature and wound healing: diphen-
hydramine (2–4 mg kg−1 PO q12h).
Supportive therapy is particularly important
in dogs with GI signs, and where degranulation
is anticipated8 (EBM IV), but is appropriate in
all patients with measurable MCT. The gastro-
protective drug sucralfate is recommended in cases
with GI signs.
4.8 Quality of life
Quality of life issues may lead to euthanasia in
patients with noncurable MCT, due to unresectable
or recurrent local disease causing local signs,
disseminated tumours causing organ dysfunction
or paraneoplastic effects. Acute deterioration and
fatality may result from anaphylaxis or gastroduo-
denal haemorrhage or perforation109 (EBM IV).
No published studies have been performed to
precisely evaluate quality of life of pets with MCT
(EBM IV). However, in one study evaluating the
efficacy of the RTK inhibitor toceranib phosphate
(Palladia®), Palladia-treated responders scored
statistically higher on health-related quality of life
versus Palladia-treated nonresponders77 (EBM I).
5 Felinemast cells tumours
MCT are the second most common cutaneous
tumours in the cat, accounting for approximately
20% of skin tumours. Two different histological
subtypes of MCT exist in the cat: the mastocytic
form, similar to MCT in dogs, and the less
common atypical form. The ‘atypical’ form was
until recently referred to as the ‘histiocytic’ form.
The mean age at development of the mastocytic
form is 10 years. There is no gender predilection
(EBM IV)8,112, (EBM III).110,111 The atypical form
of MCT occurs primarily in Siamese cats under
4 years of age. Siamese cats are also predisposed
to the development of mastocytic MCT. The
aetiology of feline MCT is unknown, but a genetic
predisposition had been proposed in the Siamese
(EBM IV).112
5.1 Clinical presentation
The typical feline cutaneous MCT is a solitary,
firm, well-circumscribed, hairless, dermal nodule
with superficial ulceration in 25% of lesions
(Panel 6). Patients may also present with a
flat, pruritic, plaque-like lesion that resembles
eosinophilic granuloma, or discrete subcutaneous
nodules8,110,113–115 (all EBM III). Intermittent
pruritus, erythema and ulceration are common and
Darier’s sign has been reported. Approximately
20% of cats present with multiple lesions.
The head and neck are the most common sites
for cutaneous MCT. Reported metastatic rates for
cutaneous MCT in cats vary considerably, ranging
from 0 to 22% (EBM III).8,110,112,113,116
Visceral MCTs are more common in the cat
than in the dog, with up to 50% of cases occurring
in visceral sites (spleen, intestine). Cats are often
systemically unwell for several months before
diagnosis. In these patients, widespread metastasis
is common. Diarrhoea is common with intestinal
MCT. A cranial mediastinal form of MCT is also
reported (EBM IV). Signs related to mast cell
degranulation are more common in visceral or
disseminated MCT8,110,113 (EBM III).
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A B
Panel 6. Examples of feline mastocytic MCT (A, B).
5.2 Clinical examination, biopsy and staging
The approach to feline MCT is similar to that in the
dog.
Cats presenting with any of the follow-
ing symptoms should be fully clinically staged,
based on lymph node aspirates, abdominal ultra-
sound and cytology, thoracic radiographs, buffy
coat smear/bone marrow aspirate if indicated
(EBM IV):
(1) Multiple nodules
(2) Palpable abdominal abnormalities
(3) Histologically diffuse/pleomorphic
tumours
(4) Splenic, intestinal or cranial mediastinal
tumours
5.3 Prognosis
The Patnaik grading system cannot be applied to
feline MCT, but histological appearance correlates
with prognosis.
Mastocytic MCTs were historically subdivided
into compact and diffuse forms. The mastocytic
form is now divided into the well-differentiated
form (formally the compact form) and the
pleomorphic form (formally referred to as the
diffuse form).
The well-differentiated form, which accounts for
50–90% of cases, is associated with a more benign
behaviour. The pleomorphic form is histologically
more anaplastic and clinically more malignant, and
carries a poorer prognosis (EBM III).8,110,112,114,116
Multiple cutaneous MCT carry a more guarded
prognosis than solitary tumours110 (EBM III).
In primary splenic MCT, long-term survival
(median of 12–19 months) is often achieved after
splenectomy, even in the face of widespread
metastasis8,117–119 (EBM III). Intestinal and
other visceral MCT are associated with a poor
prognosis8,110,113,119 (EBM II/III).
The value of proliferation indices has not been
widely assessed in feline MCT, but high mitotic rate
has been associated with aggressive behaviour115,120
(EBM II/III).
5.4 Treatment
5.4.1 Surgery
Fewer cats with MCT are cured by surgery than
dogs, but surgery remains the best option for single,
cutaneous MCTs localized in the head and/or
neck121 (EBM III). It is frequently impossible to
excise MCTs with wide margins, but this may be
less critical for histologically well-differentiated
(compact) tumours. Postsurgical recurrence rates
of 0–24% are reported (EBM III)111,114,115, (EBM
IV).122 If a preoperative biopsy suggests more
aggressive behaviour (pleomorphic or diffuse
tumours), a wide margin of excision should
be used combined with adjunctive therapy as
appropriate115 (EBM IV). Prognostic factors such as
number of lesions (multiplicity), histologic features
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(pleomorphic phenotype), KIT immunoreactivity
score, MI and Ki67 may help to identify potentially
aggressive cases of feline cutaneous MCT120
(EBM III).
In atypical (histiocytic) MCT, spontaneous
regression may occur, but if not, marginal excision
or periodical monitoring is warranted8 (EBM IV).
Splenectomy is indicated in splenic MCT, even in
the presence of metastatic disease. Reported median
survival time after splenectomy is 132 days123
(EBM III).
In the intestinal form, surgery is usually not
indicated as metastases which is usually widespread
at presentation8 (EBM IV). In rare cases with an
isolated lesion, enterectomy may be an option,
and margins of 5–10 cm on each side are
recommended8 (EBM IV).
5.4.2 Supportive therapy
As in dogs, the perioperative use of anti-H1 and H2
drugs may help to counteract the effects mast cell
degranulation8 (EBM IV).
5.4.3 Radiotherapy
There are relatively few reports of radiation therapy
of feline MCT, though it is a suggested treatment124
(EBM IV). Few cats are good candidates for
radiotherapy, since most cats have either multiple
tumours or metastases at presentation.
In addition to external beam radiation, stron-
tium 90 has been used in the treatment of soli-
tary/localized lesions with local control in 98% of
cases125 (EBM III).
5.4.4 Chemotherapy
The role of chemotherapy for palliative or adjuvant
treatment of feline MCT has not been clearly
established. Chemotherapy is generally reserved
for cats with histologically pleomorphic (diffuse),
locally invasive and/or metastatic tumours. Vin-
blastine, chlorambucil and lomustine have been
used, and one study reports an overall response
rate of 50% in cats with measurable disease treated
with lomustine, and a median duration of response
of 168 days126 (EBM III).
There is no proven role for corticosteroids in the
treatment of feline MCT.
5.4.5 Tyrosine kinase inhibitors
Mutations in the feline c-Kit proto-oncogene are
reported in up to 67% of MCTs (EBM III)127,129,130,
(EBM IV).128 Largely, there is only anecdotal data
on the use of TKIs targeting KIT in feline MCT,
and the toxicity of these drugs has not been fully
evaluated. However, a recent study has examined
the toxicity profile of masitinib. It was given at a
total dose of 50 mg per cat either daily or every
other day for 4 weeks. Proteinuria was noted in
(10%) cats when used daily, and neutropenia was
noted in 15% of cats, along with some GI toxicity129
(EBM II).
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